The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

Leukemia

Volumn 22, Issue 12, 2008, Pages 2247-2256

  Terpos, E ^a   Kastritis, E ^b   Roussou, M ^b   Heath, D ^c   Christoulas, D ^a,b   Anagnostopoulos, N ^d   Eleftherakis Papaiakovou, E ^b   Tsionos, K ^a   Croucher, P ^c   Dimopoulos, M A ^b  

^a 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d G GENNIMATAS GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIN; ANGIOPOIETIN 2; BASIC FIBROBLAST GROWTH FACTOR; BIOLOGICAL MARKER; BORTEZOMIB; COTRIMOXAZOLE; DEXAMETHASONE; DICKKOPF 1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MELPHALAN; OSTEOPONTIN; OSTEOPROTEGERIN; SOLUBLE RECEPTOR ACTIVATOR OF IMMUNOGLOBULIN ENHANCER BINDING PROTEIN LIGAND; THALIDOMIDE; UNCLASSIFIED DRUG; VALACICLOVIR; VASCULOTROPIN; ZOLEDRONIC ACID;

ADULT; AGED; ANEMIA; ANGIOGENESIS; ARTHRITIS; ARTICLE; BONE METABOLISM; BONE REMODELING; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CYTOPENIA; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FRACTURE; GASTROINTESTINAL SYMPTOM; HEART EJECTION FRACTION; HEPATITIS B; HERPES ZOSTER; HUMAN; HYPERTRANSAMINASEMIA; HYPOCALCEMIA; HYPONATREMIA; HYPOTENSION; INFECTION; INSOMNIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; MYALGIA; MYELOMA; NAUSEA; NEUTROPENIA; OSSIFICATION; OSTEOLYSIS; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREMOR;

EID: 57849161431     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.235     Document Type: Article

References (41)

1. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585-598.
2. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101: 1530-1534.
3. Mileshkin L, Honemann D, Gambell P, Trivett M, Hayakawa Y, Smyth M et al. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome. Haematologica 2007; 92: 1075-1082.
4. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377-2380.
5. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C et al The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136-1144.
6. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 2006; 236 825-831.
7. Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006; 24: 937-944.
8. Mateos MV, Hernandez JM, Hernandez MT, Gutierrez NC, Palomera L, Fuertes M et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study. Blood 2006; 108: 2165-2172.
9. Dimopoulos MA, Anagnostopoulos A, Terpos E, Repoussis P, Zomas A, Katodritou E et al. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica 2006; 91: 252-254.
10. Dimopoulos MA, Hamilos G, Zomas A, Gika D, Efstathiou E, Grigoraki V et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: An oral regimen for previously treated patients with multiple myeloma. Hematol J 2004; 5: 112-117.
11. Terpos E, Mihou D, Szydlo R, Tsimirika K, Karkantaris C, Politou M et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/ relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 2005; 19: 1969-1976.
12. Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006; 135: 688-692.
13. Terpos E, Dimopoulos MA, Sezer O. The effect of novel antimyeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007; 21: 1875-1884.
14. Kumar S, Witzig TE, Dispenzieri A, Lacy MQ, Wellik LE, Fonseca R et al. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia 2004; 18: 624-627.
15. Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H et al Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006; 66 184-191.
16. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
17. Politou MC, Heath DJ, Rahemtulla A, Szydlo R, Anagnostopoulos A, Dimopoulos MA et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 2006; 119 1728-1731.
18. Terpos E, Politou M, Szydlo R, Goldman JM, Apperley JF, Rahemtulla A. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 2003; 123: 106-109.
19. Anagnostopoulos A, Eleftherakis-Papaiakovou V, Kastritis E, Tsionos K, Bamias A, Meletis J et al. Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: The ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. Br J Haematol 2007; 137: 560-568.
20. Zangari M, Barlogie B, Burns MJ, Bolejack V, Hollmig KA, van Rhee F et al. Velcade (V)-thalidomide (T)-dexamethasone (D) for advanced and refractory multiple myeloma (MM): Long-term follow-up of Phase I-II trial UARK 2001-37: Superior outcome in patients with normal cytogenetics and no prior T. Blood 2005; 106: 717a (abstract 2552).
21. Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007; 109: 2767-2772.
22. O'Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: A single-centre experience in 211 patients. Bone Marrow Transplant 2006; 37: 731-737.
23. Rajkumar SV, Dispenzieri A. Evaluation and monitoring of response to therapy in multiple myeloma. Haematologica 2005; 90: 1305-1308.
24. Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L et al. Thalidomide and deep vein thrombosis in multiple myeloma: Risk factors and effect on survival. Clin Lymphoma 2003; 4: 32-35.
25. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
26. Terpos E, Politou M, Rahemtulla A. The role of markers of bone remodeling in multiple myeloma. Blood Rev 2005; 19: 125-142.
27. Lund T, Delkaosse JM, Abildgaard N, Kupisiewicz K, Plesner T. The bone degradation marker CTX-I shows unique properties compared to NTX-I and ICTP when used for consecutive measurements in patients with multiple myeloma. Haematologica 2008; 93 (Suppl 1): 660 abstract.
28. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J et al. Soluble receptor activator of nuclear factor kappa B ligandosteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003; 102: 1064-1069.
29. Standal T, Hjorth-Hansen H, Rasmussen T, Dahl IM, Lenhoff S, Brenne AT et al. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. Haematologica 2004; 89: 174-182.
30. Goranova-Marinova V, Goranov S, Pavlov P, Tzvetkova T. Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations. Haematologica 2007; 92: 1000-1001 [letter].
31. Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy Jr JD et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007; 25: 1121-1128.
32. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23: 4925-4935.
33. Abildgaard N, Brixen K, Kristensen JE, Eriksen EF, Nielsen JL, Heickendorff L. Comparison of five biochemical markers of bone resorption in multiple myeloma: Elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematol 2003; 120: 235-242.
34. von Metzler I, Krebbel H, Hecht M, Manz RA, Fleissner C, Mieth M et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007; 21: 2025-2034.
35. Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007; 110: 334-338.
36. Zangari M, Yaccoby S, Cavallo F, Esseltine D, Tricot G. Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma 2006; 7: 109-114.
37. Terpos E, Sezer O, Croucher PI, Dimopoulos MA. Myeloma bone disease and proteasome inhibition therapies. Blood 2007; 110: 1098-1104.
38. Humphrey EL, Williams JH, Davie MW, Marshall MJ. Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. Bone 2006; 38: 652-661.
39. Tosi P, Zamagni E, Cellini C, Parente R, Cangini D, Tacchetti P et al First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. Eur J Haematol 2006; 76: 399-404.
40. Tanaka Y, Abe M, Hiasa M, Oda A, Amou H, Nakano A et al. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: A role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 2007; 13: 816-823.
41. Heider U, Kaiser M, Müller C, Jakob C, Zavrski I, Schulz CO et al Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 2006; 77 233-238.